ETF Holdings Breakdown of SLNO

SLNO institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	16,601	USD 1,086,867
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	27,900	USD 1,826,613 -3.4%
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	287	USD 18,790 -3.4%
Total =		44,788	USD 2,932,270

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with SLNO

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of “Buy” by Brokerages

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have been assigned an average rating of “Buy” from the twelve research firms that are presently covering the firm, Marketbeat reports. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year […] - 2025-08-28 02:24:50

Notable Friday Option Activity: CSCO, SLNO, MDB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cisco Systems Inc (Symbol: CSCO), where a total volume of 148,281 contracts has been traded thus far today, a contract volume which is representative of approxim - 2025-08-15 16:27:16

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $108.70 Consensus Price Target from Brokerages

Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) has received a consensus recommendation of “Buy” from the eleven analysts that are presently covering the company, Marketbeat.com reports. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target […] - 2025-08-06 02:30:59

Soleno Therapeutics (NASDAQ:SLNO) Raised to “Hold” at Wall Street Zen

Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday. Several other analysts also recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Soleno Therapeutics […] - 2025-07-28 04:00:47

Arizona State Retirement System Has $527,000 Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Arizona State Retirement System boosted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 9.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,380 shares of the company’s stock after purchasing an additional 620 shares during the […] - 2025-07-22 07:43:03

Arizona State Retirement System Has $527,000 Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Arizona State Retirement System boosted its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 9.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,380 shares of the company’s stock after buying an additional 620 shares during […] - 2025-07-22 06:56:57

Soleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $121.00

Soleno Therapeutics (NASDAQ:SLNO – Free Report) had its target price lifted by Robert W. Baird from $105.00 to $121.00 in a research note released on Friday morning,Benzinga reports. They currently have an outperform rating on the stock. A number of other equities analysts have also weighed in on SLNO. Stifel Nicolaus increased their target price […] - 2025-07-14 03:30:49

Avior Wealth Management LLC Grows Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Avior Wealth Management LLC grew its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 72.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,410 shares of the company’s stock after buying an additional 1,437 shares during […] - 2025-06-24 04:52:53

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $106.78 Average Target Price from Brokerages

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have earned an average recommendation of “Buy” from the nine research firms that are currently covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price […] - 2025-06-17 03:08:55

California State Teachers Retirement System Has $988,000 Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

California State Teachers Retirement System boosted its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 23.6% in the fourth quarter, HoldingsChannel reports. The firm owned 21,977 shares of the company’s stock after acquiring an additional 4,201 shares during the period. California State Teachers Retirement System’s holdings in Soleno Therapeutics were worth […] - 2025-06-11 05:04:47

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 24.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,504 shares of the company’s stock […] - 2025-06-10 04:20:47

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Bought by ProShare Advisors LLC

ProShare Advisors LLC lifted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 64.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,206 shares of the company’s stock after buying an additional 2,836 shares during […] - 2025-05-30 05:06:50

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of “Buy” from Analysts

Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) has earned an average recommendation of “Buy” from the nine research firms that are covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among […] - 2025-05-20 02:31:41

Deutsche Bank AG Purchases 36,971 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Deutsche Bank AG grew its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 44.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 119,455 shares of the company’s stock after buying an additional 36,971 shares during the period. Deutsche Bank […] - 2025-05-19 05:07:01

BNP Paribas Financial Markets Purchases New Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

BNP Paribas Financial Markets purchased a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 71,320 shares of the company’s stock, valued at approximately $3,206,000. BNP Paribas Financial Markets owned 0.17% of Soleno Therapeutics […] - 2025-05-16 05:08:56

Reviewing Soleno Therapeutics (NASDAQ:SLNO) & Guided Therapeutics (OTCMKTS:GTHP)

Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Profitability This table compares Soleno Therapeutics and Guided […] - 2025-04-29 02:22:53

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Purchased by Legal & General Group Plc

Legal & General Group Plc grew its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 9.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 23,471 shares of the company’s stock after purchasing an additional 1,983 shares during the quarter. Legal & General Group Plc’s holdings in Soleno Therapeutics were worth […] - 2025-04-28 04:56:52

Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) PT at $104.67

Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) has been assigned an average rating of “Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price […] - 2025-04-28 02:39:09

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $94.57 Consensus PT from Brokerages

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have been assigned an average recommendation of “Buy” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average […] - 2025-04-03 02:35:01

Soleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading Volume Following Analyst Upgrade

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC Wainwright raised their price target on the stock from $70.00 to $100.00. HC Wainwright currently has a buy rating on the stock. Approximately 891,497 shares traded hands during mid-day trading, an increase of 40% from the previous […] - 2025-04-01 02:54:47

Swiss National Bank Boosts Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Swiss National Bank lifted its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 27.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 45,900 shares of the company’s stock after purchasing an additional 9,900 shares during the quarter. Swiss National […] - 2025-03-28 06:28:50

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of “Buy” from Brokerages

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have received an average recommendation of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target […] - 2025-03-06 05:21:27

Soleno Therapeutics (NASDAQ:SLNO) Earns “Buy” Rating from HC Wainwright

Soleno Therapeutics (NASDAQ:SLNO – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $70.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 57.52% from the company’s previous close. A number of other […] - 2025-03-05 05:04:52

Allspring Global Investments Holdings LLC Decreases Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Allspring Global Investments Holdings LLC trimmed its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 9.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 128,028 shares of the company’s stock after selling 13,396 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Soleno Therapeutics were worth $5,755,000 […] - 2025-02-20 06:24:48

Soleno Therapeutics (NASDAQ:SLNO) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Soleno Therapeutics (NASDAQ:SLNO – Free Report) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q4 2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($1.67) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at […] - 2025-02-07 06:36:55

Back to Listing

Disclaimer